Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer’s disease

References

• MuckeLNeuroscience: Alzheimer’s diseaseNature2009461726689589719829367
   PubMed Web of Science ®Google Scholar
• VetrivelKSThinakaranGMembrane rafts in Alzheimer’s disease beta-amyloid productionBiochim Biophys Acta20101801886086720303415
   PubMed Web of Science ®Google Scholar
• WhiteJAManelliAMHolmbergKHVan EldikLJLaduMJDifferential effects of oligomeric and fibrillar amyloid-beta 1–42 on astrocyte-mediated inflammationNeurobiol Dis200518345946515755672
   PubMed Web of Science ®Google Scholar
• MartinsIJBergerTSharmanMJVerdileGFullerSJMartinsRNCholesterol metabolism and transport in the pathogenesis of Alzheimer’s diseaseJ Neurochem200911161275130820050287
   PubMed Web of Science ®Google Scholar
• BuxbaumJDGeoghagenNSFriedhoffLTCholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptideJ Alzheimers Dis20013222122912214063
   PubMed Web of Science ®Google Scholar
• ParsonsRBPriceGCFarrantJKSubramaniamDAdeagbo-SheikhJAustenBMStatins inhibit the dimerization of beta-secretase via both isoprenoid- and cholesterol-mediated mechanismsBiochem J2006399220521416803455
   PubMed Web of Science ®Google Scholar
• ColeSLGrudzienAManhartIOKellyBLOakleyHVassarRStatins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanismJ Biol Chem200528019187551877015718241
   PubMed Web of Science ®Google Scholar
• FonsecaACResendeROliveiraCRPereiraCMCholesterol and statins in Alzheimer’s disease: current controversiesExp Neurol2010223228229319782682
   PubMed Web of Science ®Google Scholar
• IsingriniEDesmidtTBelzungCCamusVEndothelial dysfunction: A potential therapeutic target for geriatric depression and brain amyloid deposition in Alzheimer’s disease?Curr Opin Investig Drugs20091014655
   Google Scholar
• EvansBAEvansJEBakerS PLong-term statin therapy and CSF cholesterol levels: implications for Alzheimer’s diseaseDement Geriatr Cogn Disord200927651952419478483
   PubMed Web of Science ®Google Scholar
• ReidPCUranoYKodamaTHamakuboTAlzheimer’s disease: cholesterol, membrane rafts, isoprenoids and statinsJ Cell Mol Med200711338339217635634
   PubMed Web of Science ®Google Scholar
• Charlton-MenysVDurringtonPNSqualene synthase inhibitors: clinical pharmacology and cholesterol-lowering potentialDrugs2007671111617209661
   PubMed Web of Science ®Google Scholar
• HessDCDemchukAMBrassLMYatsuFMHMG-CoA reductase inhibitors (statins): a promising approach to stroke preventionNeurology200054479079610690964
   PubMed Web of Science ®Google Scholar
• KaesemeyerWHCaldwellRBHuangJCaldwellRWPravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actionsJ Am Coll Cardiol19993312342419935036
   PubMed Web of Science ®Google Scholar
• CombsCKJohnsonDEKarloJCCannadySBLandrethGEInflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonistsJ Neurosci200020255856710632585
   PubMed Web of Science ®Google Scholar
• YatesSLBurgessLHKocsis-AngleJAmyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microgliaJ Neurochem20007431017102510693932
   PubMed Web of Science ®Google Scholar
• BoimelMGrigoriadisNLourbopoulosAStatins reduce the neurofibrillary tangle burden in a mouse model of tauopathyJ Neuropathol Exp Neurol200968331432519225406
   PubMed Web of Science ®Google Scholar
• FassbenderKSimonsMBergmannCSimvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivoProc Natl Acad Sci U S A200198105856586111296263
   PubMed Web of Science ®Google Scholar
• PrinceSEDaselaarSMCabezaRNeural correlates of relational memory: successful encoding and retrieval of semantic and perceptual associationsJ Neurosci20052551203121015689557
   PubMed Web of Science ®Google Scholar
• YoussefSStüveOPatarroyoJCThe HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature20024206911788412422218
   PubMed Web of Science ®Google Scholar
• BerniniFPoliAPaolettiRSafety of HMG-CoA reductase inhibitors: focus on atorvastatinCardiovasc Drugs Ther200115321121811713888
   PubMed Web of Science ®Google Scholar
• DostalLAWhitfieldLRAndersonJAFertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatinFundam Appl Toxicol19963222852928921332
   PubMedGoogle Scholar
• JhooJHKimHCNabeshimaTBeta-amyloid (1–42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortexBehav Brain Res2004155218519615364477
   PubMed Web of Science ®Google Scholar
• SwardfagerWLanctôtKRothenburgLWongACappellJHerrmannNA meta-analysis of cytokines in Alzheimer’s diseaseBiol Psychiatry2010681093094120692646
   PubMed Web of Science ®Google Scholar
• BlaskoIApochalABoeckGHartmannTGrubeck-LoebensteinBRansmayrGIbuprofen decreases cytokine-induced amyloid beta production in neuronal cellsNeurobiol Dis2001861094110111741404
   PubMed Web of Science ®Google Scholar
• SastreMDewachterILandrethGENonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretaseJ Neurosci200323309796980414586007
   PubMed Web of Science ®Google Scholar
• QiaoXCumminsDJPaulSMNeuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouseEur J Neurosci200114347448211553297
   PubMed Web of Science ®Google Scholar
• GuoJTYuJGrassDde BeerFCKindyMSInfammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosisJ Neurosci200222145900590912122052
   PubMed Web of Science ®Google Scholar
• WolozinBKellmanWRuosseauPCelesiaGGSiegelGDecreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitorsArch Neurol200057101439144311030795
   PubMed Web of Science ®Google Scholar
• RockwoodKKirklandSHoganDBUse of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly peopleArch Neurol200259222322711843693
   PubMed Web of Science ®Google Scholar
• CaballeroJNahataMDo statins slow down Alzheimer’s disease? A reviewJ Clin Pharm Ther200429320921315153082
   PubMed Web of Science ®Google Scholar
• RefoloLMPappollaMALaFrancoisJA cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s diseaseNeurobiol Dis20018589089911592856
   PubMed Web of Science ®Google Scholar
• PetanceskaSSDeRosaSOlmVStatin therapy for Alzheimer’s disease: will it work?J Mol Neurosci2002191–215516112212773
   PubMed Web of Science ®Google Scholar
• GripOJanciauskieneSLindgrenSAtorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytesInfamm Res20025125862
   Web of Science ®Google Scholar
• WongBLummaWCSmithAMSiskoJTWrightSDCaiTQStatins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylationJ Leukoc Biol200169695996211404382
   PubMed Web of Science ®Google Scholar
• ZaccoATogoJSpenceK3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicityJ Neurosci20032335111041111114657168
   PubMed Web of Science ®Google Scholar